Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)

NCT05046613 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05046613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05046613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Recruiting
Start date
September 23, 2021
Completion date
April 30, 2034
Enrollment
780 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine